Literature DB >> 7711342

Continuous midazolam infusion for the management of morphine-induced myoclonus.

M T Holdsworth1, V R Adams, C M Chavez, L J Vaughan, M H Duncan.   

Abstract

OBJECTIVE: To describe a patient with morphine-induced myoclonus treated with a continuous infusion of midazolam and continued morphine dose escalation.
DESIGN: Single case report.
SETTING: Delivery, monitoring, and titration of morphine and midazolam in the patient's home by a homecare agency.
RESULTS: The use of high dosages of morphine (i.e., 500 mg/h) produced myoclonic spasms in this patient, which in turn resulted in increasing pain. To allow for continuation of effective analgesia and to control the myoclonic spasms, an infusion of midazolam was initiated and titrated. The midazolam infusion allowed for continuation of the morphine dosage and also permitted further dosage escalation. As morphine dosages were further escalated, it was also necessary to increase the midazolam infusion to control additional myoclonic spasms.
CONCLUSIONS: Use of a concomitant midazolam infusion with high doses of morphine appears to be safe and is an effective means of controlling morphine-induced myoclonus. If further dosage increase of morphine are necessary in this setting, increases in the midazolam infusion also may be required.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7711342     DOI: 10.1177/106002809502900105

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Dehydration in the terminally ill.

Authors:  R L Fainsinger; E Bruera
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

Review 2.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment.

Authors:  D Santini; G Armento; R Giusti; M Ferrara; C Moro; F Fulfaro; P Bossi; F Arena; C I Ripamonti
Journal:  ESMO Open       Date:  2020-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.